Cross-sectional and prospective relationships of apoA-I and apoB100 with subclinical atherosclerosis

2017 Fiscal Year Research-status Report

• Project/Area Number: 17K15826
• Research Institution: Shiga University of Medical Science
• Principal Investigator: ZAID MARYAM 滋賀医科大学, アジア疫学研究センター, 特任助教 (80780733)
• Project Period (FY): 2017-04-01 – 2019-03-31
• Keywords: atherosclerosis / apoA-I / apoB100

Outline of Annual Research Achievements

Thus far, accumulation and acquiring of background knowledge for this research study was done. This was done through the attendance of a joint World Congress of Epidemiology (WCE) and International Epidemiological Association (IEA), which was held in Saitama, Japan on August 19th-22nd, 2017. Information regarding important epidemiological risk factors to consider as potential confounders was acquired and helpful for our next step in measuring apoA-I and apoB100 in Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA) Japanese men. From this we have decided to combine analysis of serum samples, apolipoproteins and other biomarkers. This was done in order to gather as much information as possible from each individual while minimizing costs.

Current Status of Research Progress

3: Progress in research has been slightly delayed.

Reason

Due to the limited serum blood samples in SESSA study, we have decided to slightly delay the analysis of serum samples in order to combine measurements of apoA-I and apoB100 with other novel and traditional biomarkers that have note yet been measured, but are important in epidemiology of subclinical atherosclerosis and cardiovascular diseases.
We are now in discussion with other members of SESSA on how to best utilize serum samples. Discussions are ongoing from May 2018.

Strategy for Future Research Activity

By July 2018 we plan to send out the 853 SESSA follow-up (2010-2014) serum samples for turbidimetric immunoassay measurement at a laboratory/company. We anticipate retrieval of apoA-I and apoB100 measurements within 2 months. From there we will clean and double check data and merge it with the existing SESSA dataset.
Data analysis will commence around September 2018 and analyze prospective (longitudinal) relationship between change in apoA-I and apoB100 levels and changes in CAC, cIMT, and total carotid plaques. Manuscript write-up and article submission to international peer-reviewed journal is expected to be done by December 2018.

Causes of Carryover

Due to the limited serum blood samples in SESSA study, we have decided to slightly delay the analysis of serum samples in order to combine measurements of apoA-I and apoB100 with other novel and traditional biomarkers that have not yet been measured, but are important in epidemiology of subclinical atherosclerosis and cardiovascular diseases.
We request the unused funding to be moved to the next year fiscal funding as it is needed for the measurement costs of serum samples.